June 12, 2017

APPEAL FOR SUPPORT

Dear Partners and Friends,

Warmest greetings, and we come to you in yet another time of trial with a serious medical
condition affecting one of our members in the Regional Secretariat, Ms. Corazon D. Loste, 56
years old, who was diagnosed with Breast Cancer Stage 2 (Invasive Ductal Carcinoma) in April
2017.

Please find below the clinical

abstract discussing her diagnosis and treatment:

This is the case of CORAZON D. LOSTE, 56 years old, resident of Baguio City, female, and married, who
was diagnosed with Invasive Ductal Carcinoma, Right, Stage II, through excision biopsy.

Invasive Ductal Carcinoma is a type of Breast Cancer that originates in the milk ducts and invades the
fatty tissues of the breast outside the ducts.To prevent the spread of the cancer cells into the axillary
lymph nodes, patient was advised to undergo Modified Radical Mastectomy of the right breast, a
procedure in which the entire breast is removed including the skin, areola, nipple and most axillary lymph
nodes. Patient underwent the said operation last May 3, 2017.

The breast mass including the breast specimen was subjected to immunohistochemical analysis to
evaluate the presence of receptors on the cancer cells surface. This is essential in treatment planning
and in determining the risk of recurrence. Tests revealed an estrogen-receptor and progesterone-receptor
positive breast cancer with an equivocal HER-2/NEU result. Further testing using Fluorescent in situ
hybridization (FISH) was done to evaluate gene amplification. Results showed a HER-2 positive breast
cancer. HER-2 positive breast cancer occurs in about 20-30% of breast cancer patients. These tumors
tend to grow faster and are generally more likely to recur than tumors that do not overproduce HER-2.

Therefore, treatment plan include chemotherapy, Trastuzumab therapy, and hormonal therapy.
Chemotherapy with doxorubicin and cyclophosphamide will be given every 3 weeks for 4 cycles, while
Trastuzumab (Herceptin) therapy with Paclitaxel will be administered weekly for 12 cycles. After these,
Trastuzumab (Herceptin) which targets the HER-2 proteins will be continued to be given every 3 weeks
for 14 cycles to complete 18 cycles. Lastly, Hormonal therapy will be given for five to ten years. Close
monitoring of the patient is also needed to determine the recurrence of the cancer for the first 5 years.
The breakdown of approximate cost for each therapy are as follows:

1. Chemotherapy with Doxorubicin and Cyclophosphamide PhP 32,000.00

2. Trastuzumab (Herceptin) and Paclitaxel Therapy PhP 685,000.00
3. Trastuzumab (Herceptin) Therapy PhP1,790,000.00
4. Hormonal Therapy with Arimidex PhP 390,000.00

TOTAL: PhP 2,897,000

Annex 1: Computation of approximated cost for each therapy

Cora started her first chemotherapy treatment last June 5, 2017. She is following a diet regimen
and other doctors advise. With these projected expenses, CPA with Coras family is raising
funds to cover the cost of the 4-phase treatment. It is in this light that we are reaching out to all
partners and friends for both financial and moral support.

Some, if not most of you may have met Cora. She is an indigenous Kankanaey from Mountain
Province. She is married to Bobby Loste and they have four children: Leilene, married to
Roujahn Durante; Rosendo, Samuel and Kathleen. During her youth, Cora helped organize
students in Bontoc, Mountain Province before joining the Montanosa Research and
Development Center (MRDC) from 1988 to 1999. At MRDC, Cora helped carryout training and
organizing among indigenous peasants in Besao and Sagada, Mountain Province. She also
functioned as administrative staff.

Cora joined the CPA regional secretariat in 2001 as administrative officer. While her primary
work concerns CPAs administrative concerns, she actively contributed to CPAs program of
work in organizing, education, campaigns and advocacy. Coras commitment and dedication is
immeasurable and has contributed significantly to the CPAs work. As an activist, Cora has lived
her life of service to the people. We want Cora to regain her good health, strength, and
recover in time. With you help, support and solidarity, much can be done to support her in her
recovery. We thank you in advance for your support. We are providing CPAs bank details to
facilitate your support for Cora:

US Dollar Account
Cordillera Peoples Alliance Peso Account
5470156541 Cordillera Peoples Alliance
Banco de Oro (EPCIB) 5470161413
National Life Building Banco de Oro (EPCIB)
Session Road, Baguio City National Life Building
Swift: BNORPHMM Session Road, Baguio City


For inquiries or clarifications, please do not hesitate to get in touch with us. Again, thank you.

Respectfully,

WINDEL BOLINGET
Chairperson

Annex 1: Computation of Therapy Expenses

1. Chemotherapy (Doxorubicin + Cyclophosphamide) 8,000 per session x 4 cycles = PhP32,000

a. Chemo drugs 4,000
b. Pre-chemo meds 2,000
c. Take home meds 2000

2. Paclitaxel + Herceptin = PhP684,800

a. Paclitaxel 8,000 per session x 12 cycles = PhP96,000
b. Herceptin -
**weight: 64kg
** 1 vial of Herceptin 150mg PhP 41,600
i. Loading dose (4mg/kg) = 256mg 2 vials = PhP83,200
ii. Maintenance dose (2mg/kg) = 128mg 1 vial =
41,600 x 11 cycles = PhP457,600
c. Estimated Pre-chemo meds + Take home meds (antihistamine) = PhP48,000

3. Herceptin only = PhP 1,789,200

a. Dosage: 6mg/kg
14 cycles more to complete 18 cycles
** 64 kg x 6mg/kg = 360 mg 3 vials = PhP124,800
124,800 x 14 cycles = PhP1,747,200
b. Estimated Take-home meds (3,000 x 14 cycles)= PhP42,000

4. Hormonal therapy with Arimidex = PhP 390,000

a. Arimidex at PhP 6,500/month x atleast 5 years = PhP 390,000